Glycogen Branching Enzyme Deficiency
Learn what the condition is, how it may be detected early, how it is treated or managed, and which breeds or species are linked to it.
Condition snapshot
A concise guide to the condition’s pattern, detection, management and urgency.
Breeding advice appliesUse the screening guidance and veterinary or genetics advice before breeding an affected or at-risk animal.
This snapshot is a general guide, not a diagnosis or treatment plan. New, severe or worsening signs require veterinary assessment.
About the condition
Glycogen branching enzyme deficiency, or GBED, is a fatal autosomal recessive disorder of Quarter Horses and related breeds caused by a GBE1 variant. Without adequate branching enzyme, glycogen is formed abnormally and cannot serve as an efficient, accessible energy store. Heart, skeletal muscle and brain are especially vulnerable during fetal and neonatal life.
Many affected conceptuses are lost before birth, so GBED can appear as abortion or stillbirth. Live foals may be weak, unable to stand, hypothermic, have flexural limb deformities, seizures, respiratory failure or sudden cardiac death. Some initially nurse and seem to improve, then collapse during the first weeks or months. Laboratory findings can include low blood glucose and high muscle enzymes, but values vary and are not diagnostic by themselves.
Prematurity, neonatal sepsis, hypoxic injury, white muscle disease and other inherited myopathies can produce similar weakness. GBED is not an infection and cannot be acquired from feed. Affected foals cannot restore normal energy storage through extra carbohydrate; repeated glucose administration may temporarily support blood concentration but does not correct the enzyme defect.
Carriers are healthy. When two carriers are mated, each pregnancy has a 25% chance of an affected foal, while embryonic losses may hide the true number. No curative treatment exists and affected foals die or require humane euthanasia. The practical control is DNA testing of breeding Quarter Horses, Paints, Appaloosas and crosses with relevant ancestry, then avoiding carrier-to-carrier matings while preserving carriers through genetically clear partners.
Abnormally unbranched polysaccharide cannot release glucose efficiently during muscular and cardiac demand. This accounts for the wide spectrum from fetal loss to seizures, weakness or sudden death. Because affected pregnancies can disappear as apparently routine abortions, carrier-to-carrier matings may seem successful for years before a live characteristic foal is recognised.
Screening & Early Detection
GBED is considered in unexplained abortion, stillbirth or a weak Quarter Horse-type foal with hypothermia, seizures, limb contracture or recurrent collapse. Immediate tests include glucose, blood gas, electrolytes, creatine kinase, complete blood count, IgG and sepsis evaluation because treatable neonatal emergencies can coexist. Cardiac assessment and necropsy help characterise fatal cases.
A validated GBE1 DNA test establishes clear, carrier or affected genotype from blood or hair roots. The result is linked to the foal and, when relevant, confirmed against both parents. Muscle or other tissue can show abnormal glycogen with specialised histochemical or biochemical testing, but DNA is less invasive and suited to breeding screening.
At-risk stallions and mares are tested before mating. Reproductive loss alone cannot identify carriers, and a normal adult phenotype proves nothing because heterozygotes are unaffected. A negative test excludes the recognised mutation, not unrelated causes of weakness. Samples from abortions and stillbirths should be retained so a hidden affected pregnancy can inform future pairings.
Placental and fetal tissues from an abortion are sampled before disposal whenever parent genotypes are unknown.
Treatment & Management
Emergency glucose, warmth, oxygen, fluids, assisted nutrition and seizure control may stabilise a weak foal while sepsis, prematurity and the diagnosis are investigated. These measures do not supply functional branching enzyme. There is no diet, enzyme replacement or gene treatment capable of producing sustained normal glycogen storage in an affected horse.
Once homozygous GBED is confirmed, humane euthanasia is recommended before repeated collapse, respiratory failure or distress. Necropsy and stored DNA are valuable when confirmation was not obtained during life. The mare receives routine post-abortion or postpartum care and the premises are assessed for infectious abortion until a genetic cause is firmly established; GBED itself requires no isolation.
Prevention relies on mating decisions. Clear-to-clear and carrier-to-clear pairs cannot produce an affected foal from this variant. Two carriers are not paired, and embryos may be tested in specialised programmes. Healthy carriers require no treatment and need not be removed automatically from breeding, but their status is permanently recorded and disclosed. Related horses are tested directly rather than assigned status by reputation. After an affected foal or abortion, both parents are obligate carriers unless parentage or diagnosis is wrong, and all future matings are planned from verified results.
Breeds or species affected
American Quarter Horse
Open horse breed description, care requirements and conditions
American Paint Horse
Open horse breed description, care requirements and conditions
Appaloosa
Open horse breed description, care requirements and conditions
Quarter Pony
Open horse breed description, care requirements and conditions